Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals

OBJECTIVES: Thanks to its long half-life, dalbavancin qualifies as an optimal drug for saving costs. We aimed to assess the cost and effectiveness of dalbavancin versus the standard of care (SoC). PATIENTS AND METHODS: We conducted a multicentre retrospective study, including all hospitalized or out...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Francesca, Mazzitelli, Maria, Silvola, Sofia, Raumer, Francesca, Restelli, Umberto, Croce, Davide, Marchetti, Giulia, Cattelan, Anna Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116602/
https://www.ncbi.nlm.nih.gov/pubmed/37090914
http://dx.doi.org/10.1093/jacamr/dlad044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116602/
https://www.ncbi.nlm.nih.gov/pubmed/37090914
http://dx.doi.org/10.1093/jacamr/dlad044

Ejemplares similares